Stephen Davis is a research professor in the Dr. Phillip Frost Department of Dermatology & Cutaneous Surgery and has been Principle Investigator (PI) or Co-PI on research grants totaling over $26 million from DARPA, Canadian Defense, US Army, Office of Naval Research, NIH, NSF and various companies. Most of the performed industry studies are designed for FDA claims support for new wound care products. Examples of studies his lab has performed with companies include numerous products that are on the market today, e.g. DuoDerm and Aquacel Ag+ dressing (Convatec), Kerlix A.M.D. (Covidien Healthcare), Idodflex (Perstrop Pharma), Procellera (Vomaris Innovations) Prontosan (BBraun), Liquid Bandage (Johnson & Johnson), Mepitel & Exufiber Ag+ (Mölnlycke Health) Care, Keratec (Keratec Ltd), Benzal HP (HS Pharma), ElastoGel (Southwest Technologies), MIST Therapy System, Celleration, Inc, PuraPly AM & Apligraph (Organogenesis Inc.), SamUltrasound Dressing (Zetroz Inc.), PROcise (ArthroCare Corporation), MediHoney (Dermasciences), PolyHeal (MediWound Ltd) , Water-Gel dressing (Water-Gel Technologies), Puracyn (Innovacyn, Inc), etc.
Current Projects
Current projects include collaborations with various industry supported studies (confidential) as well as numerous Department of Defense and NIH grants.
Funding Source: Department of Defense (DoD) – Small Business Innovation Research (SBIR) grant with Arrevus Inc.
Title/Goal: Development of novel antimicrobial peptide with dual antimicrobial and wound healing activities as a topical burn wound therapeutic. We are evaluating novel antimicrobial peptides with dual antimicrobial and wound healing activities as a topical burn wound therapeutic.
Funding Source: NIH/SBIR with IFyber, LLC
Title/Goal: Development of wound care formulations for PVP/NO: A novel nitric oxide releasing platform with potent antimicrobial and anti-biofilm properties. The goal of this project is to examine the effect ofa PVP/NO treatment on wound infection and healing using porcine models.
Funding Source: DoD/SBIR with IFyber, LLC
Title/Goal: Novel Cyclic Lipopeptides for Treating Complicated Wound Infections. The goal of this study is examine novel antimicrobial peptides in a nanoparticle formulation using various porcine models.
Funding Source: DoD/BAA (Badiavas PI).
Title/Goal: Extracellular Vesicle for the Prevention of third degree Burn Wound Conversion. In collaboration with Evangelos Badiavas, MD, PhD, we are studying the use of extracellular vesicles to reduce third degree burn wound conversion. We will assess the ischemic and inflammatory state leading to burn wound conversion as well as examining microvesicles to stimulate healing, and reduce scar formation.
Funding Source: NIH – RO-1 (Velazquez PI).
Title/Goal: In collaboration with Omaida Velazquez and others at the University we are working on a study entitled Targeted cell delivery for treatment of non-healing wounds and gangrene. The goal is to develop novel delivery systems for stems cells to eliminate major amputation by promotion of wound healing and reversal of gangrene through accelerating neovascularization and tissue repair.
Funding Source: DoD with IFyber
Title/Goal: Peptide-based dressings for treatment and control of wound infection. The goals of these studies are to assistant in the development and evaluation of a peptide-based wound dressing that is expected to elicit multiple beneficial effects on traumatic wounds; importantly, inhibition of microbial colonization and biofilm elimination, suppression of local inflammation, and enhancement of the natural wound healing process.
Funding Source: DoD SBIR with Ifyber DOD
Title/Goal: A Nanolayer copper coating for prevention of Nosocomial multi-drug resistant infections. The goal of this project is to assess the effect of a novel copper treatment on wound infection and healing using porcine models.
Funding Source: DoD/SBIR First String
Title/Goal: Determining the Effects of a Novel Peptide Formulation (Granexin® gel) on the Healing of Donor Sites using a Deep Partial Thickness Wound Healing using a Porcine Model. The objective of this study is to determine the effects of a novel peptide formulation (Granexin® gel) on the healing of donor sites using a deep partial thickness wound healing using a porcine model.